6ML.F MOLECULAR PARTNERS SF 1

Healthcare Biotechnology Frankfurt Exchange
2.76 EUR
Close of Nov 12, 2026
2.68 4.31
Market cap
EUR 106M
P/E
-
P/B
1.87x
ROE
-101.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 6ML.F undervalued?

Graham number

The Graham number of MOLECULAR PARTNERS SF 1 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MOLECULAR PARTNERS SF 1 fundamental analysis

No fundamental analysis for MOLECULAR PARTNERS SF 1 yet.

MOLECULAR PARTNERS SF 1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MOLECULAR PARTNERS SF 1

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) …

Full company profile